CRISPR reveals new therapeutic target for glioblastoma
Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma rely on transforming growth factor beta-activated kinase 1 (TAK1) for survival and that inhibiting this enzyme leads to the death of the cells.
Furthermore, they have demonstrated that it is possible to reprogram other cancer cells to become dependent on TAK1 which would mean that TAK1 inhibition could destroy more of the tumour and potentially prevent a recurrence of the disease.
This early-stage research provides hope that TAK1 could be an important therapeutic target, not only in glioblastoma but also in other types of cancer.
The study was led by researchers at The Institute of Cancer Research, London, and published in the Nature journal Cell Death & Disease.
First author Dr Helene Damhofer, who is now a senior scientist at BiOrigin in Copenhagen, said: “This innovative work has provided a link that was not known before. By discovering that a subset of glioma cells with a high level of immune activation is dependent on TAK1, we have provided insight into the mechanism by which TAK1 inhibition induces cell death in the glioma cells. Excitingly, this also gives us a means by which to stratify patients, as we can predict those who will likely benefit from TAK1 inhibition.”
Hard to treat brain cancer
Glioblastoma is difficult to treat, partly because the tumours are often detected at a late stage, but there are also various biological factors at play.
Firstly, there are typically significant differences – relating to shape, genetics and behaviour – between glioblastoma cells, both across patient populations and within the same tumour. Secondly, the position of the cancer in the brain means that treatments can only reach it if they can penetrate the blood-brain barrier.
These difficulties are compounded by the poor response of glioblastomas to most cancer medications, which tends to result in tumour recurrence.
Previous work has attributed this treatment resistance to a persistent subset of cells called glioblastoma stem cells (GSCs), which can be divided into three subtypes. The mesenchymal subtype correlates with the poorest patient outcomes.
Earlier studies have also demonstrated that glioblastoma cells can shift between subtypes and that a transition to a primarily mesenchymal cell state occurs in many of the patients whose disease relapses following treatment.
In this new study, the researchers therefore aimed to identify a potential vulnerability in mesenchymal glioblastoma cells that could be exploited therapeutically.
Cancer cells dependent on TAK1
The researchers used CRISPR screening to investigate the effects of inactivating the function of thousands of genes, rather than limiting themselves to genes already known to have a role in cancer cell survival.
They discovered that the survival of many GSCs is dependent on the activity of TAK1, which seems to inhibit receptor-interacting protein kinase 1 (RIPK1). When active, RIPK1 associates with a protein complex called the caspase-8/FADD complex to induce cell death. By blocking RIPK1’s activity, TAK1 prolongs the survival of the cancerous cells.
The team was also able to identify a genetic ‘signature’ that could support treatment decisions by revealing which tumours are likely to respond well to drugs that inhibit TAK1. This signature was present in cells with high levels of immune activation, including those with a mesenchymal subtype, and the team successfully used it to predict sensitivity to a known TAK1 inhibitor.
The researchers then showed that it was possible to reprogramme other cancer cells to become dependent on TAK1 function for their survival. They did this by treating the cells with specific cytokines to mimic an immune-cell rich environment. This reprogramming serves to make a larger number of cells sensitive to treatment with TAK1 inhibitors.
Diana Spencer, Senior Digital Content Editor, DDW
